# Ascentawits

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ascentawits

- Industry: Healthcare Specialists
- Headquarters: Shenzhen, China
- Website: www.ascentawits.com
- Latest round: Series A (Feb 28, 2020)
- Investors on record: 6

## About

Based in Shenzhen, China, and established in 2014, Ascentawits is a biotechnology company that focuses on the development of tumor drugs. It has established partnerships with Shenzhen University, OBI Pharma, Shenzhen Bay Laboratory, etc. In February 2021, the company closed a pre-series B funding. In June 2023, AST-006 was acquired the NMPA implied permission to enter clinical trials. The chairman of the board and general manager, Jianxin Duan graduated from the University of Florida.

The company specializes in developing small molecule targeted coupling drugs such as AST-3424, AST-001, AST-006, and so on, which entered the industrialization stage. It has developed a targeted small molecule coupled drug platform based on AKR1C3 enzyme activation and a targeted small molecule coupled drug platform based on hypoxia activation.

The company generates revenue by providing small molecule targeted coupling drugs.

## Funding rounds

- Series A, Feb 28, 2020 — Cowin Capital, KCH Capital Management, Shenzhen Guozhong Venture Capital, Huada Gongying (Shenzhen) Equity Investment Fund Management
- Series A, Mar 27, 2017 — Sangel Capital, Zhuzhou CRRC Times Investment

## Investors

- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- Zhuzhou CRRC Times Investment (https://capitalatlas.ai/funds/zhuzhou-crrc-times-investment) — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- KCH Capital Management (https://capitalatlas.ai/funds/kch-capital-management) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Huada Gongying (Shenzhen) Equity Investment Fund Management — Series A